Please assess the completion status of the following clinical trial:

Trial Title: Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. male or female patient 35-65 years of age with an unilateral OAH requiring a THA and a healthy contralateral hip~2. body weight ≤110 kg or body mass index (BMI) ≤35 kg/m2~3. living in the Uppsala County~4. the eligible patients should have been given oral information, a written Patient Information and signed an Informed Consent~Exclusion Criteria:~1. on or previously have had bone-specific treatment, e.g. bisphosphonates, raloxifene, parathyroid hormone, strontium ranelate, during the last five years~2. patients on systemical corticosteroid for more than 3 months should not be considered~3. patients with diagnosed malignant disease during the last five years or known to have metastasis from malignant disease should be excluded~4. patients with compromised general conditions and an American Society of Anesthesiologists, ASA-score \>31 should not be regarded eligible~5. patients with known drug or alcohol abuse or regarded as socially dysfunctional, as judged by the investigator, should not be considered for the study~6. pregnant women or women planning for pregnancy or fertile women (premenopausal) without contraceptives should not be accepted for the study~7. patients that have been exposed frequently and/or have had large irradiation doses, as judged by the investigator, must not be included in the study.~8. enrolled in either another investigational drug study, in another investigational device study, or in another investigational study of an approved drug within 30 days prior to Visit 1 of the current study~9. any condition or laboratory findings which in the opinion of the Investigator makes the patient unsuitable for inclusion (for example claustrophobia)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Denosumab (Type: ACTIVE_COMPARATOR): 1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
- saline (Type: PLACEBO_COMPARATOR): 1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later

Based on this trial design, predict the completion outcome and termination type (if applicable).